Clinical trials: Clopidogrel
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
ANEURYSM CORONARY ARTERY
Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent
The purpose of this study in to evaluate efficacy and tolerability of Clopirin and clopidogrel with aspirin in Korean Patients with post-percutaneous coronary artery intervention.
- Trial name
- NCT02410083
- Testing
- Clopirin 1, Clopidogrel-Aspirin(co-administration) 1, Clopirin 2
- Volunteers
- 448 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Healthy
Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers
The primary objective of this study is to assess the effects of clopidogrel on the PK of K-877 in healthy adult subjects.
- Trial name
- NCT02922465
- Testing
- K-877, Clopidogrel
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Haemostasis, Healthy
A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to determine the feasibility of demonstrating a quantifiable change from baseline in punch biopsy-induced bleeding durations and blood loss…
- Trial name
- NCT01603342
- Testing
- clopidogrel
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Haemostasis, Healthy
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers…
- Trial name
- NCT01561950
- Testing
- eptacog alfa (activated), clopidogrel
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Novo Nordisk A/S
MCA - Middle Cerebral Artery Dissection
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
- Trial name
- NCT02953405
- Testing
- Clopidogrel
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Coronary Artery Disease (CAD)
Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
The aim of this study is to demonstrate that the combination therapy of aspirin and clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with respect to its effectiveness in inhibiting platelet…
- Trial name
- NCT01830491
- Testing
- Clopidogrel, aspirin 100mg
- Volunteers
- 162 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Thrombosis
CV004-007 Thrombosis Chamber Study
The purpose of this study is to determine whether BMS-986120, aspirin, or aspirin and clopidogrel decrease blood clotting.
- Trial name
- NCT02439190
- Testing
- BMS-986120, Aspirin, Clopidogrel
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Bioequivalence, AUC, Cmax, Pharmacokinetics
Clopidogrel Bioequivalence Study in Healthy Subjects
This study will be an open-label, randomised, three-way crossover study in healthy male and female subjects, performed at a single centre.
- Trial name
- NCT02185534
- Testing
- Clopidogrel
- Where
- Germany
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-ST Elevation Acute Coronary Syndrome
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc…
- Trial name
- NSTE-ACS (NCT02052635)
- Testing
- ticagrelor, clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
- Trial name
- NCT01603082
- Testing
- Ticagrelor, Clopidogrel
- Where
- 16 sites in United States
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Hypertension
Zainidip in Renal Artery Stenosis
To evaluate the efficacy of renal artery stent combined with standardized medical therapy as treatment for renal artery stenosis.
- Trial name
- NCT02594410
- Testing
- stent, Aspirine, Clopidogrel
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Lee's Pharmaceutical Limited
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)
This study will evaluate whether the antiplatelet effects of Aspirin 300 mg daily and Clopidogrel 75 mg daily can be reproducibly measured using several point of care platelet function assays
- Trial name
- NCT01108588
- Testing
- Aspirin, Clopidogrel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Non-ST or ST Elevation Acute Coronary Syndromes
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
- Trial name
- HouYi (NCT01864005)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Ischemic Stroke, Transient Ischemic Attack
VISSIT Intracranial Stent Study for Ischemic Therapy
The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.
- Trial name
- VISSIT (NCT00816166)
- Testing
- Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel), Aspirin and Clopidogrel (Medical therapy)
- Volunteers
- 125 people
- Sponsor
- Codman & Shurtleff
Heart Defects, Congenital
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.
- Trial name
- CLARINET (NCT00396877)
- Testing
- Clopidogrel (SR25990)
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 906 people
- Sponsor
- Sanofi
Peripheral Artery Disease, Vascular Disease
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with…
- Conditions
- Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease, Intermittent Claudication
- Trial name
- PAD (NCT02121288)
- Testing
- Ticagrelor, clopidogrel
- Sponsor
- AstraZeneca